A5008921995- Breast Cancer Treatment Studies
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Cancer Treatment and Pharmacology
- Cancer Immunotherapy and Biomarkers
- Cancer Genomics and Diagnostics
- Lung Cancer Treatments and Mutations
- Estrogen and related hormone effects
- Lung Cancer Research Studies
- Monoclonal and Polyclonal Antibodies Research
- Cancer Diagnosis and Treatment
- Genetic factors in colorectal cancer
- Pancreatic and Hepatic Oncology Research
- Cancer therapeutics and mechanisms
- Cancer, Lipids, and Metabolism
- Breast Lesions and Carcinomas
- Single-cell and spatial transcriptomics
- Hepatocellular Carcinoma Treatment and Prognosis
- BRCA gene mutations in cancer
- Inflammatory mediators and NSAID effects
- Cancer Risks and Factors
- Cancer Cells and Metastasis
- Inflammatory Biomarkers in Disease Prognosis
- Lung Cancer Diagnosis and Treatment
- Lymphoma Diagnosis and Treatment
Sun Yat-sen University
2016-2025
Sun Yat-sen University Cancer Center
2016-2025
State Key Laboratory of Oncology in South China
2015-2024
Yuxian People's Hospital
2024
Xian Yang Central Hospital
2024
University of Colorado Denver
2021-2023
University of Colorado Cancer Center
2021-2023
University Medical Center
2021
Weatherford College
2021
Shanghai Sixth People's Hospital
2008
Abstract Pulmonary lymphoepithelioma-like carcinoma (LELC) is a rare and distinct subtype of primary lung cancer characterized by Epstein-Barr virus (EBV) infection. Herein, we reported the mutational landscape pulmonary LELC using whole-exome sequencing, targeted deep sequencing single-nucleotide polymorphism arrays. We identify low degree somatic mutation but widespread existence copy number variations. reveal predominant signature 2 mutations frequent loss type I interferon genes that are...
PURPOSE The effects of metronomic chemotherapy plus endocrine therapy have yet to be elucidated through a randomized phase III clinical trial. METHODS Randomized trials were conducted at 12 centers in China from August 22, 2017, September 24, 2021, and the final follow-up date was 25, 2023. Patients with hormone receptor–positive, human epidermal growth factor receptor 2 (HER2)–negative metastatic breast cancer (MBC) who had no previous systemic setting enrolled. Participants 1:1 assigned...
Topoisomerase II alpha (TOP2A) protein has been shown to be a proliferation marker associated with tumor grade and Ki67 index. The prognostic effect of TOP2A seems different among subtypes breast cancer. current study evaluated the impact on luminal Altogether 434 stage I-II cancer patients who underwent curative surgery in Sun Yat-Sen University Cancer Center between 2007 2009 were enrolled. expression was assessed by immunohistochemistry. Clinical pathological data retrospectively...
Palbociclib, a highly selective CDK4/6 inhibitor, has been shown to be novel anti-tumor agent that suppresses breast cancer cell proliferation. However, its anti-metastasis activity remains controversial. In the present study, we evaluated whether palbociclib prevented metastasis and revealed regulatory mechanism. We found inhibited migration invasion in cells MDA-MB-231 T47D. The epithelial-mesenchymal transition (EMT) markers, vimentin Snail, were down-regulated with treatment. Moreover,...
High-level tissue tumor mutational burden (tTMB) or blood TMB (bTMB) are associated with better response of immunotherapy in non-small cell lung cancer (NSCLC) patients. However, the correlations single-region tTMB, multi-region tTMB and bTMB remain to be determined. Moreover, whether intratumor heterogeneity (ITH) has impact on should clarified. We collected tissues matched from 32 operative NSCLC evaluated through a 1021-gene panel sequencing. > 9 mutations/Mb was classified as high....
Abstract Background HER2-targeted antibody–drug conjugates (ADCs) have revolutionized the treatment landscape of metastatic breast cancer. However, efficacy these therapies may be compromised by genomic alterations. Hence, this study aims to identify factors predicting sensitivity HER2 ADC in Methods This comprehensive real-world retrospective collected clinical data from patients diagnosed with cancer and performed profiling using targeted next-generation sequencing. The analyzed...
This multicenter study aimed to investigate the efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy (ICI-Chemo group) versus alone (Chemo for patients with cancer unknown primary (CUP) in first-line setting. We included unfavorable CUP across four medical centers China. Between January 2014 December 2023, 117 were enrolled: 46 ICI-Chemo group 71 Chemo group. After a median follow-up 28.1 months, exhibited significant improvement over PFS (9.10 months vs. 6.37 months; hazard ratio...
Background: Interstitial cystitis/bladder pain syndrome (IC/BPS) is a chronic and diagnostically challenging condition with limited treatment options poor prognosis. Platelet-rich plasma (PRP) potential for IC/BPS. Nonetheless, conventional preparation methods are inefficient, necessitating an improved approach. Objective: To design effective safe protocol collecting PRP intravesical injections the of Methods: We evaluated feasibility collection from 17 patients. After venipuncture, blood...
Abstract Background Despite the impressive anti‐tumor activity of osimertinib in epidermal growth factor receptor (EGFR) T790M‐positive non‐small cell lung cancer (NSCLC) patients, 30–40% patients still show limited response. There is therefore a need to identify biomarkers that accurately predict response therapy. In this study, 54 with targeted next‐generation sequencing circulating tumor DNA before treatment and known T790M positivity were included. We investigated predictive value...
Background Triple-negative breast cancer (TNBC) represents about 19% of all cases in the Chinese population. Lack targeted therapy contributes to poorer outcomes compared with other subtypes. Comprehensive genomic profiling helps explore clinically relevant alterations (CRGAs) and potential therapeutic targets very-early-relapsed TNBC patients.Methods Formalin-fixed paraffin-embedded (FFPE) tumour tissue specimens from 23 patients 13 disease-free survival (DFS) more than 36 months were...
Transforming growth factor-beta 1 (TGF-β1) inhibits the proliferation of tumors in early stages cancers, whereas it promotes tumor and metastasis later cancers. To examine effect TGF-β1 polymorphisms on gastric cancer risk, we studied association between C−509T T+29C (Leu10Pro) risk 414 cases controls Chinese population. When overall were compared with controls, no significant difference was found genotype distributions for both examined. However, when stratified by stage, −509T +29C allele...
Real-world data of the CM regimen [cyclophosphamide (CTX) plus methotrexate (MTX)] in metronomic pattern for advanced breast cancer is limited to small-sample or retrospective studies. This study was aimed determine effectiveness and safety treating identify which patients are most likely benefit from regimen.Patients with who received at least once between January 2009 February 2019 Sun Yat-sen University Cancer Center were included. Clinicopathological characteristics collected. Overall...
Osimertinib is a potent third-generation EGFR tyrosine kinase inhibitor (TKI) with robust activity in advanced EGFR-mutant non-small cell lung cancer (NSCLC), including those T790M resistance mutation. However, broad interpatient variability was observed. This study aimed to evaluate whether genotypes affect the clinical outcomes and mechanisms T790M-positive NSCLC patients receiving osimertinib therapy.All treated our institute were screened. We included known positivity. Clinical objective...
Tamoxifen resistance in breast cancer is an unsolved problem clinical practice. The aim of this study was to determine the potential mechanisms tamoxifen through bioinformatics analysis.Gene expression profiles tamoxifen-resistant MCF-7/TR and MCF-7 cells were acquired from Gene Expression Omnibus dataset GSE26459, differentially expressed genes (DEGs) detected with R software. We conducted Ontology (GO) Kyoto Encyclopedia Genes Genomes pathway enrichment analyses using Database for...
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer (BC) patients are at a high risk of developing metastases in the brain. However, research focusing on treatment strategies for hormonal positive (HR+), HER2+ BC with brain (BM) remains limited. Thus, multi-center, prospective trial was conducted China. Women over age 18 who were naive to whole radiotherapy and had estrogen (ER)/progesterone-receptor (PgR) positive, BM treated palbociclib, fulvestrant, trastuzumab...
Selective estrogen receptor modulator (SERM)-associated nonalcoholic fatty liver disease (NAFLD) might be related to treatment efficacy in patients with breast cancer because of circulating antagonism. The aim the study was investigate relationship between NAFLD and survival outcomes who were treated tamoxifen or toremifene. This single-center, retrospective, cohort included 785 eligible received toremifene, after curative resection for cancer, at Sun Yat-sen University Cancer Center January...
To assess the prognostic significance of skin involvement in breast cancer patients with chest wall recurrence (CWR).We retrospectively analyzed clinicopathological data CWR who were diagnosed pathologically between January 2000 and April 2020. Disease-free survival (DFS) was time from radical resection for to disease recurrence. Progression-free (PFS) defined as diagnosis locally unresectable first sign progression. Persistent progression three consecutive progressions no distant organ...
Abstract Background Genetic testing plays an important role in guiding screening, diagnosis, and precision treatment of breast cancer (BC). However, the appropriate genetic criteria remain controversial. The current study aims to facilitate development suitable strategies by analyzing germline mutational profiles clinicopathological features large‐scale Chinese BC patients. Methods patients who had undergone at Sun Yat‐sen University Cancer Center (SYSUCC) from September 2014 March 2022 were...
This study aims to evaluate the efficacy and safety of a new combination treatment vinorelbine pyrotinib in human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer (MBC) provide higher level evidence for clinical practice.